A world without cancer is possible

By supporting ACRF you are Backing Brilliant research to help reach a world without cancer.

ACRF Accelerate banner ? ACRF Accelerate banner :

By supporting ACRF you are Backing Brilliant research to help reach a world without cancer.

We value your support

We are extremely thankful for the generosity of our philanthropic supporters. We are some of the way towards funding our current projects, but we need your help to reach our target.

We invite you to back brilliant cancer research with ACRF.

We value your support

We are extremely thankful for the generosity of our philanthropic supporters. We are some of the way towards funding our current projects, but we need your help to reach our target.

We invite you to back brilliant cancer research with ACRF.

What is Accelerate Why ACRF Accelerate Our projects Chat with us

CONTRIBUTE NOW

What is ACRF Accelerate?

ACRF Accelerate is our structured philanthropic initiative. ACRF Accelerate uses the generous support from people like yourself, willing to make a contribution of at least $5,000, guided by a dedicated relationship manager to back significant life-saving cancer research projects within Australia.

Why Philanthropic giving?

Philanthropic contributions are essential to accelerate progress and improve outcomes for those diagnosed with cancer. By backing brilliant cancer research through ACRF Accelerate, you are funding entire programs of pioneering cancer research.

“We know from cancer researchers that access to better technology and equipment is the key to significantly shifting the dial to improve the prevention, detection and treatment of all cancers. We look forward to working with you to secure a better future. ”

– KERRY STRYDOM, ACRF CEO

PLAY VIDEO

Why ACRF Accelerate

What we fund Our unique impact model Your involvement

Researchers tell us that it’s the technology that drives the innovations and breakthroughs in cancer research. Since 1984 we have provided $184 million to 86 projects within 44 organisations through the generosity of all our supporters working together towards a world without cancer.

The ACRF Medical Research Advisory Committee comprises world-renowned scientists and clinicians who ensure only the most deserving of projects are funded. Ultimately this gives you comfort that your donation will result in real, measurable benefits for those diagnosed with or at risk of cancer.

With input from health economics specialists, we have developed a model to articulate the impact of our supported projects. This will help you understand the value of your support and how it contributes socially, scientifically and economically.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

Customised experience and involvement

With a minimum contribution of $5,000 you can select which program to pledge your support to, or you can share your contribution across all projects through ‘untied funding’, in a bespoke approach that best aligns with your wishes.

We’ll keep you informed of progress, but you may want to go a little deeper in your understanding of the research by attending special events and tours. Your dedicated relationship manager will tailor your preferences in line with your wishes.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

Customised experience and involvement

Our six philanthropic projects for 2024

Immunotherapy Cancer Models Optimised Therapy Precision Medicine Lung Cancer Screening Molecular Theranostics

ACRF Spatial Immune-oncology Research Program

Unlocking the potential of immunotherapies for childhood cancer

$ 0

of $2,000,000 raised

The future success of cancer immunotherapy in children relies on an improved understanding of the how the elements of the TIME (e.g. immune cells, blood vessels) interact with the tumour. Understanding more about this could be the key to unlocking the potential of immunotherapy to effectively treat childhood cancers.

Help fund immunotherapy

Overview

ACRF Spatial Immune-oncology Research Program

The ACRF ASpIRe Program will leverage new ACRF funded technologies to develop high-resolution, low-cost analyses of the TIME of childhood cancers. This includes a new, innovative platform – the MACSima as well as the Olink system – which will position Australia at the forefront of delivering the first specialised translational TIME profiling program for paediatric cancers.

Download project details
Projected Impact
Human
The introduction of an immunotherapy (anti-GD2) for children with high-risk neuroblastoma alongside standard therapy has significantly improved survival rates but this is not without toxic side effects.

The ACRF ASpIRe Program has the potential to develop new immunotherapies for children that will improve outcomes and reduce toxic side effects.
Leverage
Leveraged funding totalling $2M will be provided by the Australian Genome Research Facility Limited ($250,000 cash plus $543,000 in kind); the University of New South Wales ($915,000) and the Cancer Institute NSW ($500,000) to support the development of the ACRF ASpIRe Program.
Societal
Adult survivors of childhood cancers are more likely to be in poorer health. The ACRF ASpIRe Program has the potential to greatly enhance the long-term outcomes for childhood cancer survivors thereby reducing productivity losses.

The Program also has the potential to reduce the burden on caregivers who, when considering time spent caregiving for loved ones, work absenteeism and presenteeism, experience a 23% work productivity loss because of caregiving.
Intellectual
One of the most important outputs of the ACRF ASpIRe Program will be publications to inform future research. The $2M invested by ACRF alone has a potential return of 23 publications.
“ACRF funding is an investment in innovation and new approaches to cancer research. Both in scale and in reach, the ACRF Grant program is a unique and vital part of the cancer research landscape.”

- Associate Professor Paul Ekert, Chief Investigator ACRF ASpIRe

ACRF Centre for Advanced Cancer Modelling

Developing tailored patient treatment approaches in real-time

$ 0

of $2,000,000 raised

The ACRF Centre for Advanced Cancer Modelling (ACRF CACM) will bring together clinical, research and bioengineering expertise to advance the development of cancer tissue models to inform treatment decisions.

Advance cancer models

Overview

ACRF Centre for Advanced Cancer Modelling

The ACRF Centre for Advanced Cancer Modelling will deliver new knowledge on the mechanisms of resistance to molecular and immune-based therapies in a broad range of cancers. It will also provide insights into protective memory and reveal novel therapeutic targets that can circumvent treatment resistance.

Download project details
Projected Impact
Human
In 2023 it is estimated that 165,000 Australians will be diagnosed with cancer and 51,000 will die. Precision oncology treatments, such as immunotherapies, have the potential to benefit over 8,000 Australians.

Research conducted in the ACRF Centre for Advanced Cancer Modelling will result in a better understanding of which drugs are most effective and will positively benefits patients.
Leverage
Over the last five years the research team have secured over $43M in competitive grant funding. Additional funding of $1.1M will be provided by Macquarie University to sort the Centre.

A further $500,000 will be provided by the Cancer Institute NSW to support a research specialist with experience in genomics and bioinformatics.
Societal
The ACRF Centre for Advanced Cancer Modelling has the potential to reduce the burden on caregivers who, when considering time spent caregiving for loved ones, work absenteeism and presenteeism, experience a 23% work productivity loss because of caregiving.

A precision oncology approach can deliver health benefits at a potentially affordable cost.
Intellectual
The core team alone (excluding the CI’s) has the potential to generate $804,000 in value added gain. One of the most important outputs of the ACRF Centre for Advanced Cancer Modelling will be publications to inform future research.
“This ACRF grant is an important catalyst that will expand our research expertise and capabilities by providing access to state-of-the-art equipment and cutting-edge facilities.”

- Professor Helen Rizos, Chief Investigator ACRF CACM

ACRF Centre for Optimised Cancer Therapy

Transforming decades of research into individualised treatment options

$ 0

of $1,999,998 raised

The ACRF Centre for Optimised Cancer Therapy will leverage a suite of unique resources created by the research team to understand dynamic changes of cancer during chemotherapy, immunotherapy, targeted and cellular therapies.

Fund treatments

Overview

ACRF Centre for Optimised Cancer Therapy

The ACRF Centre for Optimised Cancer Therapy (ACRF COCT), is an ambitious and highly translational initiative that seeks to refine the approach to treating patients with cancer. It will integrate the latest advances in genomics and innovative technologies to understand differences among cells within and between tumours and apply deep learning to large data sets to refine the approach to treating patients with cancer.

Download project details
Projected Impact
Human
Precision oncology treatments, such as immunotherapies, have the potential to benefit over 8,000 Australians.

Greater accuracy in identifying precision oncology treatments that will benefit patients would greatly increase this number.
Leverage
Over the last five years the research team have secured over $21 million in competitive grant funding. The investment in $2M would significantly strengthen future grant applications and secure additional funding.

A further $300,000 will be provided by Ovarian Cancer Research Foundation to support personnel for ovarian cancer research.
Societal
A precision oncology approach can deliver health benefits at a potentially affordable cost.

The use of a test that can select those patients who can benefit from a particular treatment during the early stage of the development of precision oncology drugs has been found to reduce the cost of development by $US1.1 billion.
Intellectual
Jobs in medical research are high value and knowledgebased jobs that contribute substantially to the economy. The core team alone (excluding the CI’s) has the potential to generate $603,000 in value added gain.
ACRF provides funding for new equipment which can dramatically advance the speed and significance of delivering our research findings.”

- Professor Steven Lane, Chief Investigator ACRF COCT

ACRF Centre for Precision Medicine

Accelerating new therapies from the laboratory to cancer patients

$ 0

of $1,999,997 raised

By matching the most accurate and effective treatment to each cancer patient based on the profile of the particular cancer, more patients will benefit, as treatment options will be tailored to them avoiding the “one-size-fits-all” in terms of cancer treatment.

Help fund the facility

Overview

ACRF Centre for Precision Medicine.

The ACRF Centre for Precision Medicine will utilise a “theranostic” approach of combined imaging and treatment with novel drugs to enhance therapeutic responses and exploit new technology for tumour treatment.

Download project details
Projected impact
Human
Precision oncology is a quickly developing therapy option for a variety of cancers. It has the potential to provide benefit for up to 50% of patients¹⁰, through improving both the management and outcomes for individuals.¹¹
Leverage
$2.1M invested by the ACRF has a potential return of $8.19M – $5.49M in the form of health gains and $2.7M in wider economic gains.
Societal
Theranostics has shown to be at least 29% more effective in treating prostate cancer compared to standard care.⁴ Extrapolating this across the cost of treating the four main cancers prostate, colorectal, breast and lung could see a reduction of $174M each year.¹³
Intellectual
Jobs in medical research are high value and knowledge-based jobs that contribute substantially to the economy.¹ The core team alone (excluding the CI’s) has the potential to generate $395,300 in value added gain.²
“The ACRF Centre for Precision Medicine will establish a unique and exciting capability for translation of discoveries into the clinic and provide a key technology for theranostics for multi-centre clinical trials across Australia.”

– Professor Andrew Scott AM, Chief Investigator

ACRF Lung Cancer Screening Centre of Excellence

Early detection to prevent lung cancer deaths throughout the wider community.

$ 0

of $1,999,998 raised

By taking world-first mobile lung cancer research on the road, early detection of lung cancer can happen throughout the state.

Help fund early detection

Overview

ACRF Lung Cancer Screening Centre of Excellence.

A Queensland-based, world-first mobile lung cancer research facility focused on early detection research for lung cancer – the leading cause of cancer deaths globally. This pilot program will develop and test a mobile, multi-platform lung cancer detection centre with the aim of reducing health disparities. It will ensure access to rural and remote communities and at-risk populations to ensure equal opportunity for all.

Download project details
Projected impact
Human
Prevent lung cancer deaths of approximately 4,246 Australians per year and reduce lung cancer mortality by 20%.⁹

In the first 10 years, approximately 70% of all screen-detected lung cancer will be diagnosed at an early stage.¹⁰
Leverage
UQ has pledged an additional $120,000 in funding for ACRF LUSCE over five years.¹¹
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Reduce costs associated with premature mortality by 20%, resulting in approximately $1.28 billion in savings.¹²
Intellectual
A core team of 17 Chief Investigators, 24 scientists and researchers have the potential to generate upward of $164,000¹³ in added value, and an estimated 41 publications.
“We have learned from other researchers that trucks can be an alternative way of reaching people who are at risk of lung cancer, to help with screen early detection. This comes from important work in the UK, where trucks have been shown to improve the participation rate, and to allow people to be diagnosed and cured of lung cancer early.”

– Professor Kwun Fong, Chief Investigator

ACRF Molecular Theranostics Laboratory

An emerging field of cancer research with the potential to revolutionise cancer treatment.

$ 0

of $1,500,000 raised

This laboratory will be at the forefront of theranostics, providing a revolution in cancer treatment.

Help fund the laboratory

Overview

ACRF Molecular Theranostics Laboratory.

The new ACRF Molecular Theranostics Laboratory will house world-leading research into the use of theranostics to treat cancer. A form of personalised cancer treatment for the patient, the term ‘theranostics’ refers to a combined therapy and diagnostics approach. An exciting and emerging field, theranostics has the potential to revolutionise cancer treatment, employing tumour markers to deliver a therapeutic isotope (radioactive drug) directly to tumour cells to kill them.

Download project details
Projected impact
Human
Improved prognosis of 12,595 Australians at risk of dying from solid tumours each year.¹⁴

Detection of liver cirrhosis in in approximately 69,000 Australians and the potential to prevent early death in over 2,100 Australians.¹⁵
Leverage
The Centenary Institute has pledged an additional $300,000, and the Cancer Institute New South Wales has pledged another $300,000.¹⁶
Societal
Reduce cancer costs by approximately $174 million each year across 12,000 patients.

Reduce the burden on caregivers who experience an estimated 23% reduction in work productivity, costing employers approximately $12,784 a year.¹⁷
Intellectual
A core team of 6 Chief Investigators, 13 scientists and researchers has the potential to generate $409,000 in added value, and an estimated 30.5 publications.¹⁸
“Researchers at the ACRF Molecular Theranostics Laboratory have devised a theranostic approach that we hope will work against all types of solid tumours. It has an inbuilt self-amplifying mechanism of action, meaning that it should become substantially more effective with each administration.”

– Professor Philip Hogg, Chief Investigator

ACRF Spatial Immune-oncology Research Program

Unlocking the potential of immunotherapies for childhood cancer

$ 0

of $2,000,000 raised

Help fund immunotherapy

Overview

ACRF Spatial Immune-oncology Research Program

The ACRF ASpIRe Program will leverage new ACRF funded technologies to develop high-resolution, low-cost analyses of the TIME of childhood cancers. This includes a new, innovative platform – the MACSima as well as the Olink system – which will position Australia at the forefront of delivering the first specialised translational TIME profiling program for paediatric cancers.

Download project details
Projected Impact
Human
The introduction of an immunotherapy (anti-GD2) for children with high-risk neuroblastoma alongside standard therapy has significantly improved survival rates but this is not without toxic side effects.

The ACRF ASpIRe Program has the potential to develop new immunotherapies for children that will improve outcomes and reduce toxic side effects.
Leverage
Leveraged funding totalling $2M will be provided by the Australian Genome Research Facility Limited ($250,000 cash plus $543,000 in kind); the University of New South Wales ($915,000) and the Cancer Institute NSW ($500,000) to support the development of the ACRF ASpIRe Program.
Societal
Adult survivors of childhood cancers are more likely to be in poorer health. The ACRF ASpIRe Program has the potential to greatly enhance the long-term outcomes for childhood cancer survivors thereby reducing productivity losses.

The Program also has the potential to reduce the burden on caregivers who, when considering time spent caregiving for loved ones, work absenteeism and presenteeism, experience a 23% work productivity loss because of caregiving.
Intellectual
One of the most important outputs of the ACRF ASpIRe Program will be publications to inform future research. The $2M invested by ACRF alone has a potential return of 23 publications.
“ACRF funding is an investment in innovation and new approaches to cancer research. Both in scale and in reach, the ACRF Grant program is a unique and vital part of the cancer research landscape.”

- Associate Professor Paul Ekert, Chief Investigator ACRF ASpIRe

ACRF Centre for Advanced Cancer Modelling

Developing tailored patient treatment approaches in real-time

$ 0

of $2,000,000 raised

Advance cancer models

Overview

ACRF Centre for Advanced Cancer Modelling

The ACRF Centre for Advanced Cancer Modelling will deliver new knowledge on the mechanisms of resistance to molecular and immune-based therapies in a broad range of cancers. It will also provide insights into protective memory and reveal novel therapeutic targets that can circumvent treatment resistance.

Download project details
Projected Impact
Human
In 2023 it is estimated that 165,000 Australians will be diagnosed with cancer and 51,000 will die. Precision oncology treatments, such as immunotherapies, have the potential to benefit over 8,000 Australians.

Research conducted in the ACRF Centre for Advanced Cancer Modelling will result in a better understanding of which drugs are most effective and will positively benefits patients.
Leverage
Over the last five years the research team have secured over $43M in competitive grant funding. Additional funding of $1.1M will be provided by Macquarie University to sort the Centre.

A further $500,000 will be provided by the Cancer Institute NSW to support a research specialist with experience in genomics and bioinformatics.
Societal
The ACRF Centre for Advanced Cancer Modelling has the potential to reduce the burden on caregivers who, when considering time spent caregiving for loved ones, work absenteeism and presenteeism, experience a 23% work productivity loss because of caregiving.

A precision oncology approach can deliver health benefits at a potentially affordable cost.
Intellectual
The core team alone (excluding the CI’s) has the potential to generate $804,000 in value added gain. One of the most important outputs of the ACRF Centre for Advanced Cancer Modelling will be publications to inform future research.
“This ACRF grant is an important catalyst that will expand our research expertise and capabilities by providing access to state-of-the-art equipment and cutting-edge facilities.”

- Professor Helen Rizos, Chief Investigator ACRF CACM

ACRF Centre for Optimised Cancer Therapy

Transforming decades of research into individualised treatment options

$ 0

of $1,999,998 raised

Fund treatments

Overview

ACRF Centre for Optimised Cancer Therapy

The ACRF Centre for Optimised Cancer Therapy (ACRF COCT), is an ambitious and highly translational initiative that seeks to refine the approach to treating patients with cancer. It will integrate the latest advances in genomics and innovative technologies to understand differences among cells within and between tumours and apply deep learning to large data sets to refine the approach to treating patients with cancer.

Download project details
Projected Impact
Human
Precision oncology treatments, such as immunotherapies, have the potential to benefit over 8,000 Australians.

Greater accuracy in identifying precision oncology treatments that will benefit patients would greatly increase this number.
Leverage
Over the last five years the research team have secured over $21 million in competitive grant funding. The investment in $2M would significantly strengthen future grant applications and secure additional funding.

A further $300,000 will be provided by Ovarian Cancer Research Foundation to support personnel for ovarian cancer research.
Societal
A precision oncology approach can deliver health benefits at a potentially affordable cost.

The use of a test that can select those patients who can benefit from a particular treatment during the early stage of the development of precision oncology drugs has been found to reduce the cost of development by $US1.1 billion.
Intellectual
Jobs in medical research are high value and knowledgebased jobs that contribute substantially to the economy. The core team alone (excluding the CI’s) has the potential to generate $603,000 in value added gain.
ACRF provides funding for new equipment which can dramatically advance the speed and significance of delivering our research findings.”

- Professor Steven Lane, Chief Investigator ACRF COCT

ACRF Centre for Precision Medicine

Accelerating new therapies from the laboratory to cancer patients

$ 0

of $1,999,997 raised

Help fund the facility

Overview

ACRF Centre for Precision Medicine.

The ACRF Centre for Precision Medicine will utilise a “theranostic” approach of combined imaging and treatment with novel drugs to enhance therapeutic responses and exploit new technology for tumour treatment.

Download project details
Projected impact
Human
Precision oncology is a quickly developing therapy option for a variety of cancers. It has the potential to provide benefit for up to 50% of patients¹⁰, through improving both the management and outcomes for individuals.¹¹
Leverage
$2.1M invested by the ACRF has a potential return of $8.19M – $5.49M in the form of health gains and $2.7M in wider economic gains.
Societal
Theranostics has shown to be at least 29% more effective in treating prostate cancer compared to standard care.⁴ Extrapolating this across the cost of treating the four main cancers prostate, colorectal, breast and lung could see a reduction of $174M each year.¹³
Intellectual
Jobs in medical research are high value and knowledge-based jobs that contribute substantially to the economy.¹ The core team alone (excluding the CI’s) has the potential to generate $395,300 in value added gain.²
“The ACRF Centre for Precision Medicine will establish a unique and exciting capability for translation of discoveries into the clinic and provide a key technology for theranostics for multi-centre clinical trials across Australia.”

– Professor Andrew Scott AM, Chief Investigator

ACRF Lung Cancer Screening Centre of Excellence

Early detection to prevent lung cancer deaths throughout the wider community.

$ 0

of $1,999,998 raised

By taking world-first mobile lung cancer research on the road, early detection of lung cancer can happen throughout the state.

Help fund early detection

Overview

ACRF Lung Cancer Screening Centre of Excellence.

A Queensland-based, world-first mobile lung cancer research facility focused on early detection research for lung cancer – the leading cause of cancer deaths globally. This pilot program will develop and test a mobile, multi-platform lung cancer detection centre with the aim of reducing health disparities. It will ensure access to rural and remote communities and at-risk populations to ensure equal opportunity for all.

Download project details
Projected impact
Human
Prevent lung cancer deaths of approximately 4,246 Australians per year and reduce lung cancer mortality by 20%.⁹

In the first 10 years, approximately 70% of all screen-detected lung cancer will be diagnosed at an early stage.¹⁰
Leverage
UQ has pledged an additional $120,000 in funding for ACRF LUSCE over five years.¹¹
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Reduce costs associated with premature mortality by 20%, resulting in approximately $1.28 billion in savings.¹²
Intellectual
A core team of 17 Chief Investigators, 24 scientists and researchers have the potential to generate upward of $164,000¹³ in added value, and an estimated 41 publications.
“We have learned from other researchers that trucks can be an alternative way of reaching people who are at risk of lung cancer, to help with screen early detection. This comes from important work in the UK, where trucks have been shown to improve the participation rate, and to allow people to be diagnosed and cured of lung cancer early.”

– Professor Kwun Fong, Chief Investigator

ACRF Molecular Theranostics Laboratory

An emerging field of cancer research with the potential to revolutionise cancer treatment.

$ 0

of $1,500,000 raised

This laboratory will be at the forefront of theranostics, providing a revolution in cancer treatment.

Help fund the laboratory

Overview

ACRF Molecular Theranostics Laboratory.

The new ACRF Molecular Theranostics Laboratory will house world-leading research into the use of theranostics to treat cancer. A form of personalised cancer treatment for the patient, the term ‘theranostics’ refers to a combined therapy and diagnostics approach. An exciting and emerging field, theranostics has the potential to revolutionise cancer treatment, employing tumour markers to deliver a therapeutic isotope (radioactive drug) directly to tumour cells to kill them.

Download project details
Projected impact
Human
Improved prognosis of 12,595 Australians at risk of dying from solid tumours each year.¹⁴

Detection of liver cirrhosis in in approximately 69,000 Australians and the potential to prevent early death in over 2,100 Australians.¹⁵
Leverage
The Centenary Institute has pledged an additional $300,000, and the Cancer Institute New South Wales has pledged another $300,000.¹⁶
Societal
Reduce cancer costs by approximately $174 million each year across 12,000 patients.

Reduce the burden on caregivers who experience an estimated 23% reduction in work productivity, costing employers approximately $12,784 a year.¹⁷
Intellectual
A core team of 6 Chief Investigators, 13 scientists and researchers has the potential to generate $409,000 in added value, and an estimated 30.5 publications.¹⁸
“Researchers at the ACRF Molecular Theranostics Laboratory have devised a theranostic approach that we hope will work against all types of solid tumours. It has an inbuilt self-amplifying mechanism of action, meaning that it should become substantially more effective with each administration.”

– Professor Philip Hogg, Chief Investigator

To find out more about ACRF Accelerate, download the full prospectus here.

Download now

“Having supported ACRF for a decade, what attracted me were 1) leveraging donations for best ‘bang for the buck’, 2) application of good science and 3) seeing where the money is spent. Finally, I want to ensure those with cancer are given the best chance.”

Natasha Lee, Supporter, & Natasha Lee Foundation

“We chose ACRF specifically as it is one of the Sunrise Foundation’s goals to provide philanthropic support to agencies that ensure monies received are directed efficiently where they are needed the most – i.e. with the least amount of cost. Supporting the dedicated pursuit of knowledge through research is one small way that we feel we can help to make a difference.”

– Sunrise Foundation Family

“A number of years ago, I was looking for a worthy charity to donate money to. I looked at a number of charities and ACRF stood out in the crowd due to the way they engage with their donors. I have supported them ever since. I believe that scientists, doctors and researchers benefit society in an immeasurable way and I see we can create real change through research.”

– Andrew Czarnecki, ACRF Supporter

“With Accelerate you get to see what the aim of the particular research is and where it is going to, you get to see the people behind it, it tells you the impact it has on an individual, the impact it has on families; all the things you don’t really take into consideration when someone is suffering a cancer.”

– Gordon Jackson, ACRF Supporter

Victoria Bonsey

Philanthropy Manager – National Lead

Thank you for your interest in backing brilliant cancer research. I’m here to help you make informed decisions in helping achieve a world without cancer. By listening to your wishes and motivations, I can direct your attention to the most worthwhile research projects aligned with your own objectives.